Skip to main content
Article
Use of Favipiravir to Treat Lassa Virus Infection in Macaques
Emerging Infectious Diseases
  • Kyle Rosenke, National Institutes of Health
  • Heinz Feldmann, National Institutes of Health
  • Jonna B. Westover, Utah State University
  • Patrick William Hanley, National Institutes of Health
  • Cynthia Martellaro, National Institutes of Health
  • Friederike Feldmann, National Institutes of Health
  • Greg Saturday, National Institutes of Health
  • Jamie Lovaglio, National Institutes of Health
  • Dana P. Scott, National Institutes of Health
  • Yousuke Furuta, Toyama Chemical Co.
  • Takashi Komeno, Toyama Chemical Co.
  • Brian B. Gowen, Utah State University
  • David Safronetz, Public Health Agency of Canada
Document Type
Article
Publisher
CDC
Publication Date
7-31-2018
Disciplines
Abstract

Lassa virus, the cause of Lassa fever in humans, is endemic to West Africa. Treatment of Lassa fever is primarily supportive, although ribavirin has shown limited efficacy if administered early during infection. We tested favipiravir in Lassa virus–viremic macaques and found that 300 mg/kg daily for 2 weeks successfully treated infection.

Citation Information
EID Rosenke K, Feldmann H, Westover JB, Hanley P, Martellaro C, Feldmann F, et al. Use of Favipiravir to Treat Lassa Virus Infection in Macaques. Emerg Infect Dis. 2018;24(9):1696-1699. https://dx.doi.org/10.3201/eid2409.180233